Depression
Nexstim’s TMS technology targets the left dorsolateral prefrontal cortex (DLPFC) for effective therapy in mood-related brain disorders.

Nexstim is a medical technology company building navigated transcranial magnetic stimulation with 3D navigation targeting specific brain areas.
nexstim.comCrawled Nov 18, 2026
Nexstim’s TMS technology targets the left dorsolateral prefrontal cortex (DLPFC) for effective therapy in mood-related brain disorders.
Combining MEG and nTMS helps identify safe brain resection zones for epilepsy surgery, reducing invasive monitoring risks.
Tumor growth can shift brain functions, requiring precise mapping to avoid critical areas during surgery.
Nexstim is a medical device manufacturer. Nexstim NBS 6 is an FDA-cleared and CE-marked medical device. For more information on individual regional clearances, please refer to the intended purpose and indications for use descriptions below:
Authors: Heyman A1, Laine J2, and Solomon R1 Institutions: 1 Island Psychiatry, P.C., New York, U.S.A., 2 Nexstim Plc, Helsinki, Finland Download White Paper
Press Release, Helsinki, 9 November 2026 at 9 AM (EEST)
Press Release, Helsinki, 11 November 2026 at 9 AM (EEST)
Hospital da Luz Lisboa implements Nexstim nTMS for functional brain mapping before brain surgery to identify critical areas like movement and language.
This section lists current job and career opportunities at Nexstim.
Nexstim, founded in Finland in 2000, specializes in non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS), offering precise targeting for brain treatments.
The Company founders, led by professor Risto Ilmoniemi, were researchers at the Helsinki University of Technology that has a long tradition in the multidisciplinary research of biomagnetism and neuroscience.
Nexstim develops personalized therapies and diagnostics for brain diseases and disorders.
Abteilung für Minimalinvasive Neurochirurgie Prim. Prof. Prof. h. c. Dr. Dr. med. Günther C. Feigl Intraoperatives Neuromonitoring und transkranielle Magnetstimulation Dornburggasse 90 A - 7400 Oberwart Tel: +43 (0) 57979 37753
Elimäenkatu 9 B 00510 Helsinki Finland Phone +358 9 2727 170 Fax +358 9 2727 1717
Find a SmartFocus nTMS Clinic in your country:
Nexstim processes personal data based on legitimate business interests and legal compliance.
Nexstim’s privacy policy explains how the company collects and uses personal data under applicable laws.
A U.S. medical center has chosen Nexstim’s **NBS 6 system** for advanced **clinical mapping and therapy applications**. The system supports non-invasive brain stimulation techniques used in neurological research and treatment. Nexstim specializes in neurostimulation devices for clinical and research settings.
Nordic University Hospital acquires a Nexstim NBS 6 system to advance neuroscience research. The device supports non-invasive brain stimulation studies, enabling precise experimental protocols. The hospital integrates cutting-edge technology to explore neural mechanisms and therapeutic applications.
A Finnish hospital has placed an order for Nexstim’s NBS 6 system, a non-invasive brain stimulation device. The acquisition expands Nexstim’s presence in the Nordic healthcare market. The company specializes in neurostimulation technologies for clinical and research applications.
Nexstim and Brainlab have installed advanced neuroscience technology at Hospital da Luz Lisboa in Portugal. The collaboration expands neurostimulation and navigation capabilities for clinical applications. The partnership integrates Brainlab’s neuronavigation systems with Nexstim’s neurostimulation devices to enhance precision in neurosurgical procedures.
The European University Hospital has placed an order for Nexstim’s NBS 6 non-invasive brain stimulation system. The system supports advanced neuromodulation research and clinical applications. Nexstim specializes in transcranial magnetic stimulation (TMS) technologies for neurological and psychiatric treatments.
Nordic Private Clinic adds another **NBS 6** transcranial magnetic stimulation (TMS) system to its facilities. The system, developed by **Nexstim**, supports the clinic’s growing demand for non-invasive brain stimulation therapies. The expansion aligns with rising patient volumes seeking TMS treatments for conditions like depression and anxiety.
Nexstim secures a purchase order for its NBS 6 therapy system from a new customer in the United States. The transaction marks the company’s expansion into the US market with its advanced neuromodulation technology. Nexstim specializes in non-invasive brain stimulation devices for clinical and research applications.